Related Experiment Video

Updated: Jan 18, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.8K

Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-κB/Survivin Expression in HeLa Cells

Liang Yu1, Weiqiang Guo1, Ling Liu2

  • 1Medical Research Center, Yuebei Peolple's Hospital, Shaoguan, Guangdong, People's Republic of China.

Anatomical Record (Hoboken, N.J. : 2007)
|October 1, 2019
PubMed

Insights

Bosutinib, a Src/Abl inhibitor, shows potential for treating cervical cancer by reducing tumor cell growth and inducing apoptosis. This drug targets the Src/NF-κB/survivin pathway, offering a new therapeutic option.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cervical cancer is a leading cause of cancer-related deaths in women.
  • Aberrant activation of Src kinase is linked to tumor progression in various cancers.
  • Targeting Src kinase presents a potential therapeutic strategy for cervical cancer.

Purpose of the Study:

  • To investigate the anti-tumor effects of bosutinib in cervical cancer.
  • To explore the mechanism of action of bosutinib in cervical cancer cells.

Main Methods:

  • In vitro studies using cervical cancer cell lines.
  • Assessment of cell proliferation, colony formation, and apoptosis.
  • Analysis of Src/NF-κB/survivin signaling pathway activity.

Main Results:

  • Bosutinib inhibited cervical cancer cell proliferation and colony formation in a dose-dependent manner.
  • Bosutinib induced apoptosis in cervical cancer cells.
  • Bosutinib decreased the activity of the Src/NF-κB/survivin signaling pathway.

Conclusions:

  • Bosutinib demonstrates significant anti-tumor activity against cervical cancer.
  • Targeting the Src/NF-κB/survivin pathway with bosutinib is a promising therapeutic approach.
  • Further clinical evaluation of bosutinib for cervical cancer treatment is warranted.
Keywords:
BosutinibSrccervical cancersurvivin

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.2K